Medications in use at baseline (% of patients)
| No antithrombotic treatment | VKA | Antiplatelet agents | VKA + antiplatelet | Dabigatran | |
|---|---|---|---|---|---|
| n=22 585 | 5724 | 9057 | 7424 | 227 | 153 |
| Digoxin | 4.4 | 20.3 | 13.5 | 11.9 | 10.5 |
| Amiodarone | 7.9 | 18.3 | 14.6 | 23.3 | 9.2 |
| Flecainide | 4.3 | 4.4 | 6.1 | 3.1 | 9.2 |
| Dronedarone | 0.3 | 0.7 | 0.6 | 0.0 | 0.7 |
| Other antiarrhythmic agents | 1.9 | 1.9 | 2.2 | 0.9 | 2.0 |
| Diuretics | |||||
| Low-ceiling diuretics | 10.3 | 25.6 | 20.4 | 29.1 | 11.8 |
| Thiazides | 4.8 | 9.3 | 8.4 | 4.8 | 7.2 |
| Aldosterone antagonists | 1.8 | 3.4 | 2.2 | 5.3 | 0.7 |
| β-blockers | 11.3 | 30.4 | 23.0 | 48.5 | 38.6 |
| Calcium channel blockers | |||||
| Dihydropiridines | 6.1 | 11.9 | 9.9 | 15.0 | 7.2 |
| Verapamil | 1.0 | 1.6 | 1.1 | 0.4 | 0.7 |
| Diltiazem | 1.8 | 9.3 | 5.0 | 5.7 | 6.5 |
| ACEI | 13.9 | 30.1 | 26.2 | 40.1 | 24.2 |
| ARB | 10.6 | 22.3 | 17.2 | 19.4 | 27.5 |
| Other antihypertensive drugs | 1.8 | 4.3 | 3.1 | 5.7 | 4.6 |
| Nitrates | 1.4 | 2.4 | 4.4 | 19.4 | 0.0 |
| Trimetazidine | 1.5 | 1.8 | 2.6 | 2.2 | 2.0 |
| Ivabradine | 0.1 | 0.1 | 0.3 | 0.9 | 0.0 |
| Other vasodilator agents | 0.2 | 0.4 | 0.3 | 0.4 | 0.0 |
| Statins | 11.3 | 24.3 | 22.7 | 52.4 | 22.2 |
| Other lipid-modifying agents | 1.4 | 2.0 | 1.8 | 4.0 | 2.0 |
| Oral antidiabetic agents | 5.8 | 12.8 | 10.3 | 21.1 | 12.4 |
| Insulins | 1.4 | 2.4 | 2.2 | 4.0 | 1.3 |
| Proton pump inhibitors | 25.5 | 42.9 | 53.7 | 69.2 | 32.7 |
| NSAIDs | 15.5 | 19.0 | 20.6 | 18.5 | 8.5 |
ARB, angiotensin receptor blockers; NSAID, non-steroidal anti-inflammatory drugs.